Novel Antipsychotics: Ulotaront (TAAR1 A...

Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint. References:https://pmc.ncbi.nlm.nih.gov/articles/PMC8924 ... Show More

Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry.References:Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfd ... Show More

Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry. References: https://www.ncbi.nlm.nih.gov/books/NBK534811/https://pubmed.ncbi.nlm.nih.gov/24825644/https://pubmed.ncbi.nlm.nih.gov/26798982/https://www.nejm.org/doi/full/10.1056/NEJMct08017 ... Show More

A new medication for psychosis is on the horizon. It's called KarXT and it could mean fewer side effects as well as finally some relief from difficulties with attention, concentration and memory - these are the symptoms patients often report as having the greatest impact on their ... Show More

<p>We begin with a discussion about our article of the week which comes from The Lancet and is entitled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-c ... Show More

Send us Fan MailDoes using cannabis put you at a greater risk of developing schizophrenia? Is it safe to use psychedelic-assisted therapy for psychotic disorders? Is there a difference between the psychotic experience and the psychedelic experience?In today’s episode of the Psych ... Show More

Dr. Sameer Jauhar, Senior Clinical Lecturer in Affective Disorders and Psychosis at the Institute of Psychiatry, Psychology and Neuroscience, King's College, London, and as a Consultant Psychiatrist at Maudsley NHS Foundation Trust, introduces us to schizophrenia. Explore core cl ... Show More

Interview with Merete Nordentoft, DrMedSc, author of Clinical Recovery and Long-Term Association of Specialized Early Intervention Services vs Treatment as Usual Among Individuals With First-Episode Schizophrenia Spectrum Disorder: 20-Year Follow-up of the OPUS Trial. Hosted by J ... Show More

Current treatments for depression and PTSD only suppress symptoms, if they work at all. What if we could prevent these diseases from developing altogether? Neuroscientist and TED Fellow Rebecca Brachman shares the story of her team's accidental discovery of a new class of drug th ... Show More